AGIOS PHARMACEUTICALS, INC. Letters of Credit Outstanding, Amount
AGIOS PHARMACEUTICALS, INC. (AGIO) had Letters of Credit Outstanding, Amount of $2.90 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes
us-gaap:LettersOfCreditOutstandingAmount · last filed 2026-07-30
- 2026-06-30: Letters of Credit Outstanding, Amount $2.90M.
- 2026-03-31: Letters of Credit Outstanding, Amount $2.90M.
- 2025-12-31: Letters of Credit Outstanding, Amount $2.90M.
- 2025-09-30: Letters of Credit Outstanding, Amount $2.90M.
| Period end | Letters of Credit Outstanding, Amount |
|---|---|
| 2026-06-30 | $2.90M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $2.90M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $2.90M 10-K · filed 2026-02-12 |
| 2025-09-30 | $2.90M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $2.90M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $2.90M 10-Q · filed 2025-05-01 |
| 2022-12-31 | $2.90M 10-K · filed 2023-02-23 |
| 2021-12-31 | $2.90M 10-K · filed 2022-02-24 |
| 2020-12-31 | $2.90M 10-K · filed 2021-02-25 |
| 2019-12-31 | $2.90M 10-K · filed 2020-02-19 |
| 2018-12-31 | $2.90M 10-K · filed 2019-02-14 |
| 2017-12-31 | $2.90M 10-K · filed 2018-02-14 |
| 2016-12-31 | $2.90M 10-K · filed 2017-02-16 |
| 2015-12-31 | $2.90M 10-K · filed 2016-02-26 |
| 2014-12-31 | $2.20M 10-K · filed 2015-02-24 |
| 2014-09-30 | $1.40M 10-Q · filed 2014-11-07 |
| 2013-12-31 | $571.00K 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |